{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T23:44:24Z","timestamp":1782949464812,"version":"3.54.5"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL133290"],"award-info":[{"award-number":["R01HL133290"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["1R01HL143074"],"award-info":[{"award-number":["1R01HL143074"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01AHL171136"],"award-info":[{"award-number":["R01AHL171136"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["5T32AR069516"],"award-info":[{"award-number":["5T32AR069516"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012612","name":"LSU | LSUS | LSU Health Shreveport","doi-asserted-by":"publisher","award":["110101134A"],"award-info":[{"award-number":["110101134A"]}],"id":[{"id":"10.13039\/100012612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012612","name":"LSU | LSUS | LSU Health Shreveport","doi-asserted-by":"publisher","award":["110101135A"],"award-info":[{"award-number":["110101135A"]}],"id":[{"id":"10.13039\/100012612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["26POST1560048"],"award-info":[{"award-number":["26POST1560048"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["CDA933553"],"award-info":[{"award-number":["CDA933553"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["24TPA1289331"],"award-info":[{"award-number":["24TPA1289331"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02814-1","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T23:02:33Z","timestamp":1782946953000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Osimertinib-induced cardiotoxicity is driven by HDAC-dependent epigenetic repression and rescued by vorinostat"],"prefix":"10.1038","volume":"11","author":[{"given":"Angelica","family":"Toro Cora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind Singh","family":"Bhati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8149-3895","authenticated-orcid":false,"given":"Allen Sam","family":"Titus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Jaiswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baldeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7989-577X","authenticated-orcid":false,"given":"Prachi","family":"Umbarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Y.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshan","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinkun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh K.","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sultan","family":"Tousif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8980-9874","authenticated-orcid":false,"given":"Hind","family":"Lal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"2814_CR1","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3390\/ijms23010441","volume":"23","author":"A Choksey","year":"2021","unstructured":"Choksey, A. & Timm, K. N. Cancer therapy-induced cardiotoxicity-a metabolic perspective on pathogenesis, diagnosis and therapy. Int. J. Mol. Sci. 23, 441 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"2814_CR2","doi-asserted-by":"publisher","first-page":"e000665","DOI":"10.1161\/JAHA.113.000665","volume":"3","author":"VS Hahn","year":"2014","unstructured":"Hahn, V. S., Lenihan, D. J. & Ky, B. Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies. J. Am. Heart Assoc. 3, e000665 (2014).","journal-title":"J. Am. Heart Assoc."},{"key":"2814_CR3","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1093\/eurheartj\/ehaa006","volume":"41","author":"J Lopez-Sendon","year":"2020","unstructured":"Lopez-Sendon, J. et al. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur. Heart J. 41, 1720\u20131729 (2020).","journal-title":"Eur. Heart J."},{"key":"2814_CR4","doi-asserted-by":"crossref","unstructured":"Metibemu, D. S. et al. Exploring receptor tyrosine kinases-inhibitors in cancer treatments. Egypt. J. Med. Hum. Genet. 20, 35 (2019).","DOI":"10.1186\/s43042-019-0035-0"},{"key":"2814_CR5","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.2174\/1871520622666220408090541","volume":"22","author":"A Unnisa","year":"2022","unstructured":"Unnisa, A., Chettupalli, A. K., Hussain, T. & Kamal, M. A. Recent advances in epidermal growth factor receptor inhibitors (EGFRIs) and their role in the treatment of cancer: a review. Anticancer Agents Med. Chem. 22, 3370\u20133381 (2022).","journal-title":"Anticancer Agents Med. Chem."},{"key":"2814_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5732\/cjc.010.10553","volume":"30","author":"L Yan","year":"2011","unstructured":"Yan, L., Rosen, N. & Arteaga, C. Targeted cancer therapies. Chin. J. Cancer 30, 1\u20134 (2011).","journal-title":"Chin. J. Cancer"},{"key":"2814_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejpb.2015.03.018","volume":"93","author":"E Perez-Herrero","year":"2015","unstructured":"Perez-Herrero, E. & Fernandez-Medarde, A. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Eur. J. Pharm. Biopharm. 93, 52\u201379 (2015).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"2814_CR8","doi-asserted-by":"publisher","first-page":"675","DOI":"10.3892\/mco.2016.800","volume":"4","author":"ZI Chen","year":"2016","unstructured":"Chen, Z. I. & Ai, D. I. Cardiotoxicity associated with targeted cancer therapies. Mol. Clin. Oncol. 4, 675\u2013681 (2016).","journal-title":"Mol. Clin. Oncol."},{"key":"2814_CR9","doi-asserted-by":"publisher","first-page":"515","DOI":"10.46747\/cfp.6807515","volume":"68","author":"SL Shuel","year":"2022","unstructured":"Shuel, S. L. Targeted cancer therapies: clinical pearls for primary care. Can. Fam. Physician 68, 515\u2013518 (2022).","journal-title":"Can. Fam. Physician"},{"key":"2814_CR10","doi-asserted-by":"publisher","first-page":"10008","DOI":"10.3390\/ijms251810008","volume":"25","author":"H Dickerson","year":"2024","unstructured":"Dickerson, H., Diab, A. & Al Musaimi, O. Epidermal growth factor receptor tyrosine kinase inhibitors in cancer: current use and future prospects. Int. J. Mol. Sci. 25, 10008 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2814_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11936-018-0649-4","volume":"20","author":"IB Rhea","year":"2018","unstructured":"Rhea, I. B. & Oliveira, G. H. Cardiotoxicity of novel targeted chemotherapeutic agents. Curr. Treat. Options Cardiovasc. Med. 20, 53 (2018).","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"2814_CR12","doi-asserted-by":"crossref","unstructured":"Van Leeuwen, M. T. et al. Cardiovascular toxicity of targeted therapies for cancer: an overview of systematic reviews. JNCI Cancer Spectr. 4, pkaa076 (2020).","DOI":"10.1093\/jncics\/pkaa076"},{"key":"2814_CR13","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","volume":"17","author":"J Herrmann","year":"2020","unstructured":"Herrmann, J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat. Rev. Cardiol. 17, 474\u2013502 (2020).","journal-title":"Nat. Rev. Cardiol."},{"key":"2814_CR14","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.3390\/ijms23052815","volume":"23","author":"A Grela-Wojewoda","year":"2022","unstructured":"Grela-Wojewoda, A., Pacholczak-Madej, R., Adamczyk, A., Korman, M. & Puskulluoglu, M. Cardiotoxicity induced by protein kinase inhibitors in patients with cancer. Int. J. Mol. Sci. 23, 2815 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"2814_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40265-015-0533-4","volume":"76","author":"SL Greig","year":"2016","unstructured":"Greig, S. L. Osimertinib: first global approval. Drugs 76, 263\u2013273 (2016).","journal-title":"Drugs"},{"key":"2814_CR16","doi-asserted-by":"publisher","first-page":"i20","DOI":"10.1093\/annonc\/mdx704","volume":"29","author":"J Remon","year":"2018","unstructured":"Remon, J., Steuer, C. E., Ramalingam, S. S. & Felip, E. Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. Ann. Oncol. 29, i20\u2013i27 (2018).","journal-title":"Ann. Oncol."},{"key":"2814_CR17","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.3390\/jcm14051754","volume":"14","author":"A Agbarya","year":"2025","unstructured":"Agbarya, A. et al. Real-world data on osimertinib-associated cardiac toxicity. J. Clin. Med. 14, 1754 (2025).","journal-title":"J. Clin. Med."},{"key":"2814_CR18","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jaccao.2019.10.006","volume":"1","author":"K Anand","year":"2019","unstructured":"Anand, K., Ensor, J., Trachtenberg, B. & Bernicker, E. H. Osimertinib-induced cardiotoxicity: a retrospective review of the FDA adverse events reporting system (FAERS). JACC CardioOncol. 1, 172\u2013178 (2019).","journal-title":"JACC CardioOncol."},{"key":"2814_CR19","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/S1470-2045(16)30508-3","volume":"17","author":"G Goss","year":"2016","unstructured":"Goss, G. et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 17, 1643\u20131652 (2016).","journal-title":"Lancet Oncol."},{"key":"2814_CR20","doi-asserted-by":"publisher","first-page":"e2448364","DOI":"10.1001\/jamanetworkopen.2024.48364","volume":"7","author":"CY Lin","year":"2024","unstructured":"Lin, C. Y. et al. Cardiac events and survival in patients with EGFR-mutant non-small cell lung cancer treated with osimertinib. JAMA Netw. Open 7, e2448364 (2024).","journal-title":"JAMA Netw. Open"},{"key":"2814_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2020.02.003","volume":"2","author":"K Kunimasa","year":"2020","unstructured":"Kunimasa, K. et al. Cardiac adverse events in EGFR-mutated non-small cell lung cancer treated with osimertinib. JACC CardioOncol. 2, 1\u201310 (2020).","journal-title":"JACC CardioOncol."},{"key":"2814_CR22","doi-asserted-by":"publisher","first-page":"1177003","DOI":"10.3389\/fphar.2023.1177003","volume":"14","author":"P Li","year":"2023","unstructured":"Li, P. et al. Acute osimertinib exposure induces electrocardiac changes by synchronously inhibiting the currents of cardiac ion channels. Front. Pharm. 14, 1177003 (2023).","journal-title":"Front. Pharm."},{"key":"2814_CR23","doi-asserted-by":"publisher","first-page":"e22301","DOI":"10.1097\/MD.0000000000022301","volume":"99","author":"S Shinomiya","year":"2020","unstructured":"Shinomiya, S., Kaira, K., Yamaguchi, O., Ishikawa, K. & Kagamu, H. Osimertinib induced cardiomyopathy: a case report. Medicine 99, e22301 (2020).","journal-title":"Medicine"},{"key":"2814_CR24","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3390\/medicina58020312","volume":"58","author":"A Fukuo","year":"2022","unstructured":"Fukuo, A., Imamura, T., Onoda, H. & Kinugawa, K. Successful management of osimertinib-induced heart failure. Medicina 58, 312 (2022).","journal-title":"Medicina"},{"key":"2814_CR25","first-page":"38","volume":"9","author":"K Patel","year":"2023","unstructured":"Patel, K. et al. Osimertinib-induced biventricular cardiomyopathy with abnormal cardiac MRI findings: a case report. Cardiooncology 9, 38 (2023).","journal-title":"Cardiooncology"},{"key":"2814_CR26","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-20-0103","volume":"19","author":"N Floc\u2019h","year":"2020","unstructured":"Floc\u2019h, N. et al. Osimertinib, an irreversible next-generation EGFR tyrosine kinase inhibitor, exerts antitumor activity in various preclinical NSCLC models harboring the uncommon EGFR mutations G719X or L861Q or S768I. Mol. Cancer Ther. 19, 2298\u20132307 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"2814_CR27","doi-asserted-by":"crossref","unstructured":"deAlmeida, A. C., van Oort, R. J. & Wehrens, X. H. Transverse aortic constriction in mice. J. Vis. Exp. 38, 1729 (2010).","DOI":"10.3791\/1729"},{"key":"2814_CR28","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/iub.1180","volume":"65","author":"AM Orogo","year":"2013","unstructured":"Orogo, A. M. & Gustafsson, A. B. Cell death in the myocardium: my heart won\u2019t go on. IUBMB Life 65, 651\u2013656 (2013).","journal-title":"IUBMB Life"},{"key":"2814_CR29","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1161\/CIRCRESAHA.122.321504","volume":"132","author":"S Tousif","year":"2023","unstructured":"Tousif, S. et al. Ponatinib Drives cardiotoxicity by S100A8\/A9-NLRP3-IL-1beta mediated inflammation. Circ. Res. 132, 267\u2013289 (2023).","journal-title":"Circ. Res."},{"key":"2814_CR30","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/cvr\/cvz006","volume":"115","author":"AP Singh","year":"2019","unstructured":"Singh, A. P. et al. Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies. Cardiovasc. Res. 115, 966\u2013977 (2019).","journal-title":"Cardiovasc. Res."},{"key":"2814_CR31","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3390\/cancers11040513","volume":"11","author":"Y Muta","year":"2019","unstructured":"Muta, Y., Matsuda, M. & Imajo, M. Divergent dynamics and functions of ERK MAP kinase signaling in development, homeostasis and cancer: lessons from fluorescent bioimaging. Cancers 11, 513 (2019).","journal-title":"Cancers"},{"key":"2814_CR32","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1016\/j.bbamcr.2011.03.010","volume":"1813","author":"X Zhang","year":"2011","unstructured":"Zhang, X., Tang, N., Hadden, T. J. & Rishi, A. K. Akt, FoxO and regulation of apoptosis. Biochim. Biophys. Acta 1813, 1978\u20131986 (2011).","journal-title":"Biochim. Biophys. Acta"},{"key":"2814_CR33","doi-asserted-by":"publisher","first-page":"7666","DOI":"10.1093\/nar\/gku501","volume":"42","author":"J Loughery","year":"2014","unstructured":"Loughery, J., Cox, M., Smith, L. M. & Meek, D. W. Critical role for p53-serine 15 phosphorylation in stimulating transactivation at p53-responsive promoters. Nucleic Acids Res. 42, 7666\u20137680 (2014).","journal-title":"Nucleic Acids Res."},{"key":"2814_CR34","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1093\/toxsci\/kfn157","volume":"106","author":"Y Will","year":"2008","unstructured":"Will, Y. et al. Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicol. Sci. 106, 153\u2013161 (2008).","journal-title":"Toxicol. Sci."},{"key":"2814_CR35","first-page":"1286","volume":"11","author":"XY Meng","year":"2021","unstructured":"Meng, X. Y. et al. Pinin promotes tumor progression via activating CREB through PI3K\/AKT and ERK\/MAPK pathway in prostate cancer. Am. J. Cancer Res. 11, 1286\u20131303 (2021).","journal-title":"Am. J. Cancer Res."},{"key":"2814_CR36","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.3390\/cells11132111","volume":"11","author":"L He","year":"2022","unstructured":"He, L. et al. Activation of autophagic flux maintains mitochondrial homeostasis during cardiac ischemia\/reperfusion injury. Cells 11, 2111 (2022).","journal-title":"Cells"},{"key":"2814_CR37","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.yjmcc.2019.03.008","volume":"130","author":"J Yang","year":"2019","unstructured":"Yang, J. et al. HDAC inhibition induces autophagy and mitochondrial biogenesis to maintain mitochondrial homeostasis during cardiac ischemia\/reperfusion injury. J. Mol. Cell. Cardiol. 130, 36\u201348 (2019).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"2814_CR38","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1002\/cncr.32744","volume":"126","author":"H Zang","year":"2020","unstructured":"Zang, H. et al. Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589). Cancer 126, 2024\u20132033 (2020).","journal-title":"Cancer"},{"key":"2814_CR39","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1161\/RES.0000000000000473","volume":"129","author":"A Asnani","year":"2021","unstructured":"Asnani, A. et al. Preclinical models of cancer therapy-associated cardiovascular toxicity: a scientific statement from the American Heart Association. Circ. Res. 129, e21\u2013e34 (2021).","journal-title":"Circ. Res."},{"key":"2814_CR40","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1080\/14796694.2024.2370239","volume":"21","author":"JQ Cai","year":"2024","unstructured":"Cai, J. Q. et al. Cardiovascular toxicity of anaplastic lymphoma kinase inhibitors for patients with non-small cell lung cancer: a network meta-analysis. Future Oncol. 21, 1125\u20131135 (2024).","journal-title":"Future Oncol."},{"key":"2814_CR41","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s40261-018-0709-2","volume":"38","author":"J Li","year":"2018","unstructured":"Li, J. & Gu, J. Cardiovascular toxicities with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of 77 randomized controlled trials. Clin. Drug Investig. 38, 1109\u20131123 (2018).","journal-title":"Clin. Drug Investig."},{"key":"2814_CR42","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1586\/erc.09.48","volume":"7","author":"MA Sussman","year":"2009","unstructured":"Sussman, M. A. Mitochondrial integrity: preservation through Akt\/Pim-1 kinase signaling in the cardiomyocyte. Expert Rev. Cardiovasc. Ther. 7, 929\u2013938 (2009).","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"2814_CR43","doi-asserted-by":"publisher","first-page":"951539","DOI":"10.1155\/2012\/951539","volume":"2012","author":"D Montaigne","year":"2012","unstructured":"Montaigne, D., Hurt, C. & Neviere, R. Mitochondria death\/survival signaling pathways in cardiotoxicity induced by anthracyclines and anticancer-targeted therapies. Biochem. Res. Int. 2012, 951539 (2012).","journal-title":"Biochem. Res. Int."},{"key":"2814_CR44","doi-asserted-by":"publisher","first-page":"6392763","DOI":"10.1155\/2019\/6392763","volume":"2019","author":"ML Huang","year":"2019","unstructured":"Huang, M. L. et al. The role of the antioxidant response in mitochondrial dysfunction in degenerative diseases: cross-talk between antioxidant defense, autophagy, and apoptosis. Oxid. Med. Cell. Longev. 2019, 6392763 (2019).","journal-title":"Oxid. Med. Cell. Longev."},{"key":"2814_CR45","doi-asserted-by":"publisher","first-page":"945142","DOI":"10.3389\/fcvm.2022.945142","volume":"9","author":"M Liu","year":"2022","unstructured":"Liu, M. et al. Mitochondrial dysfunction in heart failure and its therapeutic implications. Front. Cardiovasc. Med. 9, 945142 (2022).","journal-title":"Front. Cardiovasc. Med."},{"key":"2814_CR46","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jphs.2024.07.007","volume":"156","author":"M Kondo","year":"2024","unstructured":"Kondo, M. et al. Inorganic sulfides prevent osimertinib-induced mitochondrial dysfunction in human iPS cell-derived cardiomyocytes. J. Pharm. Sci. 156, 69\u201376 (2024).","journal-title":"J. Pharm. Sci."},{"key":"2814_CR47","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1161\/CIRCULATIONAHA.119.040740","volume":"140","author":"Y Guo","year":"2019","unstructured":"Guo, Y. et al. Cardiomyocyte homeodomain-interacting protein kinase 2 maintains basal cardiac function via extracellular signal-regulated kinase signaling. Circulation 140, 1820\u20131833 (2019).","journal-title":"Circulation"},{"key":"2814_CR48","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.yjmcc.2019.03.020","volume":"130","author":"F Ahmad","year":"2019","unstructured":"Ahmad, F. et al. Cardiomyocyte-GSK-3alpha promotes mPTP opening and heart failure in mice with chronic pressure overload. J. Mol. Cell. Cardiol. 130, 65\u201375 (2019).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"2814_CR49","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1172\/JCI41407","volume":"120","author":"J Zhou","year":"2010","unstructured":"Zhou, J. et al. GSK-3alpha directly regulates beta-adrenergic signaling and the response of the heart to hemodynamic stress in mice. J. Clin. Invest. 120, 2280\u20132291 (2010).","journal-title":"J. Clin. Invest."},{"key":"2814_CR50","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.yjmcc.2008.09.121","volume":"45","author":"H Lal","year":"2008","unstructured":"Lal, H. et al. Stretch-induced regulation of angiotensinogen gene expression in cardiac myocytes and fibroblasts: opposing roles of JNK1\/2 and p38alpha MAP kinases. J. Mol. Cell. Cardiol. 45, 770\u2013778 (2008).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"2814_CR51","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ijcard.2012.09.131","volume":"168","author":"H Lal","year":"2013","unstructured":"Lal, H. et al. Caveolin and beta1-integrin coordinate angiotensinogen expression in cardiac myocytes. Int. J. Cardiol. 168, 436\u2013445 (2013).","journal-title":"Int. J. Cardiol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02814-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02814-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02814-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T23:02:37Z","timestamp":1782946957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02814-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2814"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02814-1","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.U. is currently employed by AstraZeneca, MD, USA. A.T.C., A.S.B., A.S.T., A.J., B.S., D.Y.L., R.S., Q.Z., S.K.V., S.T. and H.L. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"258"}}